By Frank Prenesti
Date: Wednesday 28 May 2025
(Sharecast News) - UK pharma giant GSK and its partner Spero Therapeutics on Wednesday said it had ended a late-stage trial of an experimental drug for complicated urinary tract infections early after it met its main target.
4basebio reports strong full-year progress | 27-May-2025 | ShareCast |
Avacta pushes back annual results due to auditor... | 27-May-2025 | ShareCast |
EU recommends AstraZeneca bladder cancer treatme... | 27-May-2025 | ShareCast |
Poolbeg Pharma extends cash runway after raising... | 23-May-2025 | ShareCast |
GSK's COPD treatment approved by FDA | 23-May-2025 | ShareCast |
Results of Haleon 2025 Annual General Meeting | 28-May-2025 | 18:00 | RNS |
Form 8.3 - BENCHMARK HOLDINGS PLC | 28-May-2025 | 12:38 | RNS |
GSK stops Phase 3 trial on cUTIs for efficacy | 28-May-2025 | 12:00 | RNS |
Form 8.3 - BENCHMARK HOLDINGS PLC | 28-May-2025 | 11:06 | RNS |
Form 8.3 - Benchmark Holdings plc | 28-May-2025 | 10:49 | RNS |
Questor :GW Pharmaceuticals | 04-Dec-2014 | Telegraph |
Questor : Hikma Pharmaceuticals | 13-Mar-2014 | Telegraph |
Investment Column:BTG | 06-Oct-2011 | The Independent |
Investment Column:Genus | 09-Sep-2011 | The Independent |
Questor :Dechra Pharmaceuticals | 08-Sep-2011 | Telegraph |
Price | 20,642.14 |
Closing Price Change | -110.16 |
% Change | -0.53 % |
28-May-25 Close | 20,642.14 |
You are here: research